STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Nov. 30, 2012	Nov. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,003,942)	$ (5,125,902)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation	513	531
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.	4,276,728	4,762,103
Warrants issued for services	159,896
Changes in operating assets and liabilities
Accounts payable	40,712	(35,638)
Accrued liabilities	(12,250)	10,365
NET CASH USED BY OPERATING ACTIVITIES	(538,343)	(388,541)
CASH FLOWS FROM FINANCING ACTIVITIES
Contribution of capital	523,682	387,199
NET CASH PROVIDED BY FINANCING ACTIVITIES	523,682	387,199
NET DECREASE IN CASH	(14,661)	(1,342)
CASH AT BEGINNING OF PERIOD	17,297	17,476
CASH AT END OF PERIOD	$ 2,636	$ 16,134